Schott Pharma stock edges higher after recent MDAX weakness

Published on 09/10/2026 at 17:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Schott Pharma stock gained 0.2 percent to EUR 23.55 on Xetra in morning trading on September 10, 2026, after a 1.1 percent dip on September 7, 2026. The move comes as the MDAX recently slipped 1.55 percent, highlighting sector volatility.

Pop-Art-Comic zeigt Techniker im Reinraum an Fertigspritzen-Karussell — SCHOTT Pharma (DE000A3ENQ51) inszeniert einen Pop-Art-Comic mit Techniker am Fertigspritzen-Karussell in einem sterilen Reinraum, Illustration mit AI erstellt.

Schott Pharma stock (ISIN DE000A3ENQ51) was quoted at EUR 23.55 on Xetra in morning trading on September 10, 2026, up 0.2 percent from the session open at EUR 23.50 and 2.6 percent above the close of EUR 22.95 recorded on September 7, 2026.

Stock stabilizes after recent pullback

According to finanzen.net, the Schott Pharma share traded in green on Xetra at 09:07 on September 10, 2026, gaining 0.2 percent to EUR 23.55 after starting the session at EUR 23.50.

The same overview from finanzen.net states that Schott Pharma reached a 52-week high of EUR 23.75 on August 28, 2026, so the current price of EUR 23.55 leaves the stock just EUR 0.20, or 0.8 percent, below that recent peak.

MDAX context and recent volatility

A recent market commentary highlights that the MDAX index declined 1.55 percent to 32,040.45 points on September 9, 2026, reflecting weaker sentiment in German mid-cap stocks, while Schott Pharma had already recorded a 1.1 percent loss at EUR 22.95 on September 7, 2026, underlining that the stock was not immune to the broader pressure.

In that earlier Xetra session on September 7, 2026, Schott Pharma traded between a low of EUR 22.74 and a high of EUR 23.20 before closing near the upper third of the intraday range at EUR 22.95, which investors can now compare with the intraday high of EUR 23.55 quoted on September 10, 2026.

Earnings expectations as a pivotal factor

Analyst consensus cited by finanzen.net suggests that Schott Pharma is expected to earn EUR 0.983 per share in fiscal year 2026, giving investors a concrete yardstick for valuing the stock against its current price level.

This expectation for EPS in 2026 serves as a forward-looking fundamental figure, complementing the short-term trading data and indicating that the market is pricing Schott Pharma not only on daily volatility but also on the anticipated profit profile for the current year.

Closing view on Schott Pharma stock

As of September 10, 2026, the reference price for Schott Pharma stock on its primary listing Xetra stands at EUR 23.55, in a range close to the 52-week high of EUR 23.75, illustrating that the share has recovered from the EUR 22.95 close on September 7, 2026 and remains supported despite recent MDAX weakness.